UPDATE: JP Morgan Upgrades Teva To Neutral, Notes 'We remain fairly bearish on the longer-term setup for the company between its lack of growth-drivers (Ajovy underperforming expectations so far, lingering LOEs, etc.) and still high-leverage'
Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing email@example.com
Benzinga · 11/12/2019 14:32